The Association of Clinical Research Organizations (ACRO) and its
members are committed to collaborating with biopharmaceutical
organizations worldwide to develop vaccines and anti-viral therapies to prevent, diagnose, and treat COVID-19.
The Association of Clinical Research Organizations (ACRO) represents companies at the forefront of global clinical research. ACRO members are committed to innovation in clinical development and thought leadership in research policy on topics like RBM and RBQM.
Click here for ACRO’s latest statements on the COVID-19 pandemic.
Click here to see how member companies are responding to COVID-19.
Half of all clinical trials occur in the US. ACRO works with US legislators and regulators to ensure a positive regulatory environment that supports high-quality, safe and ethical clinical research. More »
ACRO engages with European regulators, connecting its members with critical stakeholders. We support the clinical research industry and provide CRO expertise. More »
ACRO’s CRO Forum is a formal mechanism to enable clinical research organizations to interact with TransCelerate BioPharma Inc. on a range of issues that impact the industry. More »
In Europe and the US, ACRO gathers government leaders and key stakeholders to inform, educate and promote the unique contributions of clinical research and technology companies. More »
We help create a predictable, enabling business environment. ACRO’s proactive agenda is focused on policy outcomes that advance specific operational interests of ACRO members. More »
ACRO’s Global Data Protection & Privacy Committee advances issues of data privacy, protection and security, and how the industry interprets policies and prepares for upcoming legislation. More »
Get ACRO’s free quarterly newsletter to stay informed about our work and the industry.
We help create a global regulatory and business environment
where ACRO members succeed
May 6, 2020 – (Washington, DC) – In an effort to fight the global COVID-19 pandemic, over 150 employees from clinical research…
Washington DC – The Association of Clinical Research Organizations (ACRO) is pleased to announce that its Board of Directors has elected Alistair…
On Wednesday, October 23, 2019, ACRO hosted a Congressional Briefing on Capitol Hill. With the help of the Congressional Research & Development…
Developing, executing and overseeing clinical trials is a complex process. Yet it is essential to gain reliable evidence from clinical trials to…
A new report based on a survey of ACRO members reveals that Risk-Based Monitoring (RBM) makes clinical trial quality review more efficient…
On July 17, 2019, under cooperative agreement with the FDA, the Duke-Margolis Center for Health Policy (Duke Margolis) held a public workshop. The event, titled Improving the Implementation of Risk-Based Monitoring Approaches of Clinical Investigations, aimed to identify opportunities to improve Risk Based Monitoring (RBM) implementation and solicit stakeholder input on the challenges, barriers, and enablers that impact the successful adoption of RBM.
